Drug news
UCB will not market SYN 118 for Parkinsons Disease
UCB will not exercise its option to acquire rights to SYN 118 from Biotie Therapeutics as the drug did not show an improvement in Parkinsons Disease motor function compared to placebo in its Phase IIa trial.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.